FR13C0035I1 - - Google Patents

Info

Publication number
FR13C0035I1
FR13C0035I1 FR13C0035C FR13C0035I1 FR 13C0035 I1 FR13C0035 I1 FR 13C0035I1 FR 13C0035 C FR13C0035 C FR 13C0035C FR 13C0035 I1 FR13C0035 I1 FR 13C0035I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR13C0035I1 publication Critical patent/FR13C0035I1/fr
Application granted granted Critical
Publication of FR13C0035I2 publication Critical patent/FR13C0035I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
FR13C0035C 2003-08-05 2013-07-04 Nouveaux derives d'insuline Active FR13C0035I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301129 2003-08-05
US49545103P 2003-08-14 2003-08-14
EP04739008A EP1660531A2 (en) 2003-08-05 2004-07-22 Novel insulin derivatives

Publications (2)

Publication Number Publication Date
FR13C0035I1 true FR13C0035I1 (cs) 2013-08-09
FR13C0035I2 FR13C0035I2 (fr) 2014-03-07

Family

ID=34117520

Family Applications (2)

Application Number Title Priority Date Filing Date
FR13C0035C Active FR13C0035I2 (fr) 2003-08-05 2013-07-04 Nouveaux derives d'insuline
FR13C0038C Active FR13C0038I1 (fr) 2003-08-05 2013-07-05 Nouveaux derives d'insuline

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR13C0038C Active FR13C0038I1 (fr) 2003-08-05 2013-07-05 Nouveaux derives d'insuline

Country Status (18)

Country Link
US (3) US7615532B2 (cs)
EP (3) EP2107069B1 (cs)
JP (1) JP4463814B2 (cs)
KR (1) KR101159559B1 (cs)
AU (2) AU2004261353B2 (cs)
BE (2) BE2013C035I2 (cs)
BR (1) BRPI0413276B8 (cs)
CA (1) CA2531988C (cs)
CY (5) CY1113850T1 (cs)
FR (2) FR13C0035I2 (cs)
HU (1) HUS1300033I1 (cs)
IL (1) IL172980A (cs)
LU (2) LU92213I2 (cs)
MX (1) MXPA06001283A (cs)
NO (5) NO340925B1 (cs)
PL (1) PL2107069T3 (cs)
RU (1) RU2518460C2 (cs)
WO (1) WO2005012347A2 (cs)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241019A1 (en) * 2003-07-25 2006-10-26 Bridon Dominique P Long lasting insulin derivatives and methods thereof
JP4463814B2 (ja) 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
WO2006082205A1 (en) * 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
EP2256130B1 (en) * 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
ATE519780T1 (de) * 2005-12-28 2011-08-15 Novo Nordisk As Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
WO2007096431A1 (en) * 2006-02-27 2007-08-30 Novo Nordisk A/S Insulin derivatives
WO2007104736A2 (en) * 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
EP2015722B1 (en) 2006-04-28 2016-11-16 Avent, Inc. Antimicrobial site dressings
AU2007247109B2 (en) 2006-05-09 2012-03-15 Novo Nordisk A/S Insulin derivative
CN101437849B (zh) * 2006-05-09 2015-09-30 诺沃-诺迪斯克有限公司 胰岛素衍生物
US8796205B2 (en) 2006-05-09 2014-08-05 Novo Nordisk A/S Insulin derivative
JP5097900B2 (ja) * 2006-06-27 2012-12-12 独立行政法人物質・材料研究機構 有機酸又はこれらの誘導体の活性エステル体の製造方法
EP2049149B1 (en) 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylated extended insulins
DK2074141T3 (en) 2006-09-22 2016-11-28 Novo Nordisk As The protease resistant insulin analogues.
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
WO2008145730A1 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
AU2008288413B2 (en) 2007-08-15 2013-09-26 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
JP5721432B2 (ja) * 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
CN101157725B (zh) * 2007-10-24 2012-07-25 中国药科大学 人胰岛素类似物的制备方法及用途
WO2009060071A1 (en) 2007-11-08 2009-05-14 Novo Nordisk A/S Insulin derivative
MX2010005245A (es) 2007-11-16 2010-06-01 Novo Nordisk As Composiciones farmaceuticas que comprenden peptidos glp-1 o exendin-4 y un peptido de insulina basal.
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
EP2910569B1 (en) 2008-03-18 2016-10-05 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
WO2010029159A1 (en) 2008-09-12 2010-03-18 Novo Nordisk A/S Method of acylating a peptide or protein
EP2352513B1 (en) * 2008-10-30 2016-09-14 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
RU2525393C2 (ru) 2009-01-23 2014-08-10 Ново Нордиск А/С Производные fgf21 со связующим альбумина а-в-с-d-e- и их применение
CN102666579A (zh) 2009-10-30 2012-09-12 诺沃—诺迪斯克有限公司 降钙素基因相关肽的衍生物
JP5908847B2 (ja) * 2010-01-12 2016-04-26 ノヴォ ノルディスク アー／エス インスリンペプチドを経口投与するための医薬組成物
WO2011101277A1 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Conjugated proteins
ES2582590T3 (es) 2010-02-16 2016-09-13 Novo Nordisk A/S Método de purificación
WO2011141407A1 (en) 2010-05-10 2011-11-17 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
WO2011146973A1 (en) 2010-05-25 2011-12-01 Monash University Insulin analogues
EP2585483A1 (en) 2010-06-23 2013-05-01 Novo Nordisk A/S Human insulin containing additional disulfide bonds
CN104693302A (zh) 2010-06-23 2015-06-10 诺沃—诺迪斯克有限公司 包含额外的二硫键的胰岛素衍生物
EP2585484A1 (en) 2010-06-23 2013-05-01 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
CN103154024A (zh) 2010-10-15 2013-06-12 诺沃—诺迪斯克有限公司 新型n末端修饰的胰岛素衍生物
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
RS59423B1 (sr) 2010-10-27 2019-11-29 Novo Nordisk As Lečenje dijabetesa melitusa korišćenjem insulinskih injekcija davanih u različitim intervalima ubrizgavanja
WO2012080320A1 (en) 2010-12-14 2012-06-21 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
CN103370075A (zh) 2011-02-15 2013-10-23 诺沃—诺迪斯克有限公司 长效il-1受体拮抗剂
KR20140020292A (ko) * 2011-03-28 2014-02-18 노보 노르디스크 에이/에스 신규 글루카곤 유사체
JP6030630B2 (ja) 2011-04-14 2016-11-24 ノヴォ ノルディスク アー／エス 経口ペプチド送達のための脂肪酸アシル化アミノ酸
EP2720711A1 (en) 2011-06-15 2014-04-23 Novo Nordisk A/S Multi substituted insulins
US8541368B2 (en) 2011-09-23 2013-09-24 Novo Nordisk A/S Glucagon analogues
RU2014127270A (ru) * 2011-12-15 2016-02-10 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Аналог человеческого инсулина и его ацилированное производное
EP2794648A1 (en) 2011-12-21 2014-10-29 Novo Nordisk A/S N-terminally modified insulin derivatives
BR112014025132A2 (pt) 2012-04-11 2017-07-11 Novo Nordisk As formulações de insulina
US20160031962A1 (en) * 2012-04-20 2016-02-04 Kleomenis K. Barlos Solid phase peptide synthesis of insulin using side chain achored lysine
BR112014026442A8 (pt) 2012-05-01 2018-01-16 Novo Nordisk As combinação para alcançar o controle glicêmico, seu uso, e composição farmacêutica.
WO2014009316A1 (en) 2012-07-09 2014-01-16 Novo Nordisk A/S Novel use of insulin derivatives
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
US20150265710A1 (en) 2012-10-17 2015-09-24 Novo Nordisk A/S Fatty Acid Acylated D-Amino Acids for Oral Peptide Delivery
MX360317B (es) 2012-12-21 2018-10-29 Sanofi Sa Derivados de exendina-4 funcionalizada.
CN105188736A (zh) * 2013-03-20 2015-12-23 诺和诺德股份有限公司 胰岛素给药方案
RS59124B1 (sr) 2013-04-18 2019-09-30 Novo Nordisk As Stabilni, produženi koagonisti glp-1/glukagonskih receptora za medicinsku upotrebu
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
CA2926701A1 (en) 2013-10-07 2015-04-16 Novo Nordisk A/S Novel derivative of an insulin analogue
FR3013049B1 (fr) 2013-11-14 2015-11-13 You-Ping Chan Analogue de l'insuline glargine
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
CN106029088A (zh) 2014-02-18 2016-10-12 诺和诺德股份有限公司 稳定的胰高血糖素类似物以及用于治疗低血糖的用途
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
US20180244743A1 (en) 2015-08-25 2018-08-30 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
WO2017032795A1 (en) 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
CN114478747B (zh) 2016-08-02 2024-06-14 江苏恒瑞医药股份有限公司 一种人胰岛素或其类似物的酰化衍生物
WO2018096164A1 (en) 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
JP2019535791A (ja) 2016-11-28 2019-12-12 ノヴォ ノルディスク アー／エス 血糖コントロールの改善並びに急性及び長期糖尿病合併症の低減のためのインスリンデグルデク
EP3544683A1 (en) 2016-11-28 2019-10-02 Novo Nordisk A/S Insulin degludec in cardiovascular conditions
SI3554534T1 (sl) 2016-12-16 2021-09-30 Novo Nordisk A/S Farmacevtski sestavki, ki vsebujejo inzulin
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
JP2021513330A (ja) 2018-02-09 2021-05-27 江蘇恒瑞医薬股▲ふん▼有限公司 ヒトインスリンアナログのコドン最適化前駆体遺伝子およびシグナルペプチド遺伝子
US20210198311A1 (en) 2018-05-24 2021-07-01 Jiangsu Hengrui Medicine Co., Ltd. Method for preparing precursor of recombinant human insulin or analogue thereof
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
JP7410891B2 (ja) 2018-06-26 2024-01-10 ノボ・ノルデイスク・エー／エス 基礎インスリン滴定のための投与推奨を提供するシステム
KR102666154B1 (ko) 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
TW202434620A (zh) 2019-07-31 2024-09-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
CN118420743A (zh) 2019-12-30 2024-08-02 甘李药业股份有限公司 胰岛素衍生物
UA129395C2 (uk) 2020-05-15 2025-04-09 Елі Ліллі Енд Компані Ацильовані сполуки інсуліну пролонгованої дії
CN113773398B (zh) * 2020-06-10 2023-05-23 宁波鲲鹏生物科技有限公司 一种德谷胰岛素衍生物及其应用
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
US20250000948A1 (en) 2021-11-15 2025-01-02 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023143458A1 (zh) 2022-01-28 2023-08-03 甘李药业股份有限公司 酰化胰岛素
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
WO2025104600A1 (en) * 2023-11-15 2025-05-22 Ambio, Inc. Insulin analogs for the treatment of human metabolic disorder and disease

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1212679B (de) 1957-08-03 1966-03-17 Novo Terapeutisk Labor As Verfahren zur Herstellung von Insulinloesungen
GB1042194A (en) 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5605884A (en) * 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
DE69019534T2 (de) 1989-12-21 1995-09-21 Novonordisk As Insulinzubereitungen, die nikotinsäure oder nikotinamid enthalten.
DK45590D0 (cs) 1990-02-21 1990-02-21 Novo Nordisk As
JP3193398B2 (ja) 1991-07-23 2001-07-30 サンデン株式会社 ショ−ケ−ス
JP2950617B2 (ja) 1991-12-20 1999-09-20 ノボ ノルディスク アクティーゼルスカブ 成長ホルモンおよびヒスチジンを含んでなる安定化医薬製剤
EP1132404A3 (en) * 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) * 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
WO1996010417A1 (en) 1994-10-04 1996-04-11 Novo Nordisk A/S PREPARATIONS CONTAINING AspB28 HUMAN INSULIN AND NICOTINAMIDE
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5830999A (en) * 1995-01-26 1998-11-03 Regents Of The University Of California Stabilization of insulin through ligand binding interations
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
DE69629210T2 (de) 1995-03-17 2004-04-22 Novo Nordisk A/S Insulinabkömmlinge
DK2275119T3 (da) 1995-07-27 2013-11-11 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5898267A (en) * 1996-04-10 1999-04-27 Mcdermott; Kevin Parabolic axial lighting device
US5866538A (en) * 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
WO1998002460A1 (en) * 1996-07-11 1998-01-22 Novo Nordisk A/S Selective acylation method
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
DK0821006T3 (da) * 1996-07-26 2004-08-16 Aventis Pharma Gmbh Insulinderivater med öget zinkbinding
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
JP2001518915A (ja) 1997-03-20 2001-10-16 ノボ ノルディスク アクティーゼルスカブ インシュリンと吸収増強剤の共沈殿による治療用粉末の調整法
ATE219942T1 (de) 1997-03-20 2002-07-15 Novo Nordisk As Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält
HUP0000547A3 (en) * 1997-03-20 2002-11-28 Novo Nordisk As Zinc free insulin crystals for use in pulmonary compositions
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
SI0884053T1 (en) 1997-06-13 2003-02-28 Eli Lilly And Company Stable insulin formulations
US6451762B1 (en) * 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
US20020155994A1 (en) * 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
ID24890A (id) 1997-10-24 2000-08-31 Lilly Co Eli Komposisi-komposisi insulin yang tidak dapat larut
HUP0004096A3 (en) * 1997-10-24 2001-12-28 Novo Nordisk As Aggregates of human insulin derivatives and pharmaceutical compositions comprising thereof
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
WO1999034821A1 (en) * 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
DE69920767T2 (de) 1998-10-16 2006-02-02 Novo Nordisk A/S Stabile konzentrierte Insulin Präparationen zur pulmonaren Verabreichung
WO2000048635A1 (en) * 1999-02-22 2000-08-24 Baxter International Inc. Novel albumin-free factor viii formulations
AU4450700A (en) 1999-04-27 2000-11-10 Eli Lilly And Company Insulin crystals for pulmonary administration
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US6652886B2 (en) * 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE60224284T2 (de) 2001-06-28 2008-12-18 Novo Nordisk A/S Stabile formulierung von modifiziertem glp-1
HUP0700126A2 (en) 2001-12-20 2007-06-28 Lilly Co Eli Insulin molecule having protracted time action
US8003605B2 (en) * 2002-03-13 2011-08-23 Novo Nordisk A/S Minimising body weight gain in insulin treatment
ATE496064T1 (de) * 2002-05-07 2011-02-15 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
US20050232899A1 (en) * 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR100615389B1 (ko) 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
CA2502378A1 (en) 2002-10-29 2004-05-13 Alza Corporation Stabilized, solid-state polypeptide particles
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
CA2515294A1 (en) 2003-02-07 2004-08-19 Ajinomoto Co., Inc. Therapeutic agents for diabetes
ATE473279T1 (de) 2003-02-19 2010-07-15 Novartis Pharma Gmbh In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
JP2006519252A (ja) * 2003-03-04 2006-08-24 ザ・テクノロジー・デヴェロップメント・カンパニー・リミテッド 薬物送達系および細胞療法
JP4658041B2 (ja) 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液体組成物
US20050054818A1 (en) * 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
JP4463814B2 (ja) * 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
SI2107069T1 (sl) 2003-08-05 2013-04-30 Novo Nordisk A/S Novi inzulinski derivati
CA2534028A1 (en) 2003-08-14 2005-02-24 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
EP1663295A2 (en) 2003-09-01 2006-06-07 Novo Nordisk A/S Stable formulations of peptides
ES2229931B1 (es) * 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
WO2005047508A1 (en) * 2003-11-14 2005-05-26 Novo Nordisk A/S Processes for making acylated insulin
BRPI0418115A (pt) 2003-12-23 2007-04-17 Pharmacia Corp formulação lìquida estável de hormÈnio de crescimento
JP5022213B2 (ja) 2004-03-12 2012-09-12 バイオデル， インコーポレイテッド 迅速に作用する薬物送達組成物
BRPI0510527A (pt) 2004-06-01 2007-10-30 Ares Trading Sa método de estabilização de proteìnas
BRPI0513332A (pt) 2004-08-12 2008-05-06 Schering Corp formulação de interferon peguilado estável
SI1778723T1 (sl) 2004-08-17 2013-02-28 Regeneron Pharmaceuticals, Inc. Formulacije IL-1 antagonista
ES2575984T3 (es) 2004-11-12 2016-07-04 Novo Nordisk A/S Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal
WO2006053906A1 (en) 2004-11-22 2006-05-26 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
EP1838290A2 (en) 2005-01-21 2007-10-03 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
EP2256130B1 (en) * 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
ATE519780T1 (de) 2005-12-28 2011-08-15 Novo Nordisk As Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
WO2007096431A1 (en) * 2006-02-27 2007-08-30 Novo Nordisk A/S Insulin derivatives
CA2649109A1 (en) 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
AU2007247109B2 (en) * 2006-05-09 2012-03-15 Novo Nordisk A/S Insulin derivative
US9034818B2 (en) * 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
MX2010005245A (es) * 2007-11-16 2010-06-01 Novo Nordisk As Composiciones farmaceuticas que comprenden peptidos glp-1 o exendin-4 y un peptido de insulina basal.
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物

Also Published As

Publication number Publication date
CA2531988A1 (en) 2005-02-10
EP2107069B1 (en) 2013-01-16
US20060183668A1 (en) 2006-08-17
NO2024003I1 (no) 2024-01-16
CY2013027PI1 (el) 2015-11-04
BE2013C035I2 (cs) 2023-12-14
KR101159559B1 (ko) 2012-06-26
NO2018002I1 (no) 2018-01-11
US7615532B2 (en) 2009-11-10
AU2004261353B2 (en) 2009-12-10
US8828923B2 (en) 2014-09-09
LU92226I2 (fr) 2015-04-29
CY2013027I2 (el) 2024-09-20
CY2013029PI1 (el) 2015-11-04
MXPA06001283A (es) 2006-04-11
NO2018002I2 (no) 2018-08-20
PL2107069T3 (pl) 2013-06-28
AU2010200497B2 (en) 2014-10-23
RU2008152033A (ru) 2010-07-10
NO340925B1 (no) 2017-07-17
LU92213I9 (cs) 2018-11-19
EP2264065B1 (en) 2017-03-08
CY2013027I1 (el) 2024-09-20
NO2024004I1 (no) 2024-01-16
HUS1300033I1 (hu) 2016-08-29
US20100009899A1 (en) 2010-01-14
BE2013C038I2 (cs) 2023-12-14
CY2013029I1 (cs) 2024-09-20
EP2107069A3 (en) 2009-11-25
LU92226I9 (cs) 2018-11-19
NO2018003I1 (no) 2018-01-11
CY2013027PI2 (el) 2015-11-04
US20140349925A1 (en) 2014-11-27
CA2531988C (en) 2016-06-28
LU92213I2 (fr) 2013-08-23
JP4463814B2 (ja) 2010-05-19
RU2518460C2 (ru) 2014-06-10
EP2107069A2 (en) 2009-10-07
EP2264065A2 (en) 2010-12-22
WO2005012347A2 (en) 2005-02-10
BRPI0413276A (pt) 2006-10-10
FR13C0035I2 (fr) 2014-03-07
BRPI0413276B8 (pt) 2021-05-25
WO2005012347A3 (en) 2005-04-14
CY2013029PI2 (el) 2015-11-04
AU2004261353A1 (en) 2005-02-10
EP1660531A2 (en) 2006-05-31
EP2264065A3 (en) 2011-07-27
NO20061026L (no) 2006-03-02
IL172980A0 (en) 2006-06-11
IL172980A (en) 2013-10-31
BRPI0413276B1 (pt) 2020-03-03
JP2007523881A (ja) 2007-08-23
KR20060132543A (ko) 2006-12-21
CY2013029I2 (el) 2024-09-20
CY1113850T1 (el) 2015-11-04
FR13C0038I1 (fr) 2013-08-09
AU2010200497A1 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
CY2013029I1 (cs)
BE2013C075I2 (cs)
BE2013C069I2 (cs)
BE2013C067I2 (cs)
BE2013C036I2 (cs)
BE2013C034I2 (cs)
JP2004080992A5 (cs)
JP2004134051A5 (cs)
JP2003329713A5 (cs)
JP2004044803A5 (cs)
JP2004101514A5 (cs)
JP2004003075A5 (cs)
IN2006CH02600A (cs)
JP2004136363A5 (cs)
JP2004007401A5 (cs)
JP2004124696A5 (cs)
DE50310392D1 (cs)
JP2004092902A5 (cs)
JP2004118176A5 (cs)
JP2004177925A5 (cs)
JP2003219554A5 (cs)
AU2002322913A1 (cs)
AU2002327736A1 (cs)
AU2002311957A1 (cs)
AU2002316235A1 (cs)